Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00289627 · ClinicalTrials.gov registry record · Phase 2

A Single Arm Study of Ipilimumab Monotherapy in Patients With Previously Treated Unresectable Stage III or IV Melanoma

A Phase 2 study of Melanoma, sponsored by Bristol-Myers Squibb.

Completed
Registry status
Phase 2
Development phase
155
Enrollment target
20
Study locations

NCT00289627 is a Phase 2 study of Melanoma that has completed, run by Bristol-Myers Squibb. The registered enrollment target is 155 participants, below the 706-participant average among 266 other Melanoma trials with a reported enrollment target (78% lower). The trial reports 20 study locations across 13 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00289627, a Phase 2 study of Melanoma, has completed, sponsored by Bristol-Myers Squibb.

COMPLETED
Registry status
Phase 2
Development phase
155 participants
Enrollment target
20
Study locations

Study Summary

The purpose of this clinical research study is to evaluate the Best Overall Response Rate (BORR), (as per modified WHO criteria) in patients with previously treated melanoma-Stage III (unresectable) or Stage IV melanoma receiving 10 mg/kg of ipilimumab. The safety of this product will also be evaluated.

Conditions Studied

Melanoma

Interventions

  • DRUG ipilimumab (MDX-010, BMS-734016)

Study Locations (20)

Other

  • Local Institution - Salzburg
  • Local Institution - Vienna
  • Local Institution - Wels
  • Local Institution - Turku
  • Local Institution - Genova
  • Local Institution - Meldola

California

  • - San Francisco
  • - Santa Monica

Illinois

  • - Chicago
  • - Park Ridge

Arkansas

  • - Little Rock

Indiana

  • - Goshen

Kentucky

  • - Hazard

New Mexico

  • - Albuquerque

New York

  • - New York

Trial Details

FieldValue
Enrollment Target 155 participants
Start Date 2006-04
Est. Completion 2007-07
Phase Phase 2

Sponsor

Bristol-Myers Squibb

1,025 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT00289627

The ClinicalTrials.gov registry entry for NCT00289627 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 155 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 706-participant average among 266 other Melanoma trials with a reported enrollment target (78% lower). The listed sponsor is Bristol-Myers Squibb, which has 1,025 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Melanoma appearing as the primary indexed condition, and to 1 intervention - of which ipilimumab (MDX-010, BMS-734016) is the first listed.

NCT00289627 reports 20 study locations spanning 13 distinct geographic areas - top geographies include Other, California, Illinois.

Frequently Asked Questions

What is clinical trial NCT00289627 about?

NCT00289627 is a clinical study titled "A Single Arm Study of Ipilimumab Monotherapy in Patients With Previously Treated Unresectable Stage III or IV Melanoma". The purpose of this clinical research study is to evaluate the Best Overall Response Rate (BORR), (as per modified WHO criteria) in patients with previously treated melanoma-Stage III (unresectable) or Stage IV melanoma receiving 10 mg/kg of ipilimumab. The safety of this product will also be evalua...

What is the current status of trial NCT00289627?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 155 participants. The study started on 2006-04. Estimated completion is 2007-07.

What conditions does trial NCT00289627 study?

This clinical trial studies the following conditions: Melanoma.

What interventions are being tested in trial NCT00289627?

The interventions under investigation include: ipilimumab (MDX-010, BMS-734016) (DRUG).

Who is sponsoring clinical trial NCT00289627?

This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00289627 being conducted?

This trial has 20 study locations across Arkansas, California, Illinois, Indiana, Kentucky. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Melanoma

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Melanoma

All registered trials for this condition

Arkansas

All trials with a study site in Arkansas

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.